Abstract 1562P
Background
Breast cancer (BC) is the leading cause of cancer deaths in women. Current BC screening includes women over 50, but up to 20% of all BCs occur in younger women. Moreover, current mammography-based BC screening addresses up to 58% of all BC cases. Therefore, there is a need for new preventative screening strategies that are also cost-effective. In an international Be RIGHT with breast cancer risk management (BRIGHT) study, we used a polygenic risk score (PRS)-based screening to identify high-risk women in a population that does not attend routine mammography to show that PRS-based BC screening is cost-effective and has clinical utility.
Methods
In Estonia, 799 participants aged 35-49 were enrolled in the study between 2022-2023. For PRS testing, the AnteBC test (Antegenes OÜ) was used. The PRS was calculated based on 2803 BC-related genetic variants. Participants also self-filled a questionnaire about previous family cancer history for monogenic pathogenic variant (MPV) testing. All participants received a report with relevant clinical recommendations based on PRS levels. Both participants and investigators had the opportunity to fill in online feedback questionnaires.
Results
Based on PRS testing, 15.9% needed to start BC screening earlier and 58.8% according to national guidelines. From attended mammographies (154), 127 had no and 16 had benign findings. Five biopsies were taken and one stage 0 in situ intraductal BC was diagnosed. 80 participants received MPV testing, 5.7% had disease-related genetic findings. 98.3% of participants agreed that information provided was clear and sufficient, and 71.4% said they were coping well with knowing their genetic risks. 89% of investigators agreed that genetic risk in BC prevention is important based on the experience gained in BRIGHT study. 61% of investigators would definitely use the AnteBC test in clinical practice, time and need for extra knowledge were brought out as limiting factors.
Conclusions
The results of the BRIGHT study in Estonia indicate that PRS-based BC screening is feasible, has clinical utility and healthcare systems are ready for implementation. In Estonia, the addition of PRS into BC screening is planned within next few years.
Clinical trial identification
The BRIGHT study has been registered in the ISRCTN registry under ID ISRCTN29884654. Registration date 13.01.2023.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
European Commission via EIT Health (project #220720) and the Estonian Research Council PRG555 grant.
Disclosure
P. Padrik: Financial Interests, Institutional, Leadership Role: OÜ Antegenes. A. Paas, K. Kruuv-Käo, S. Sõber, A. Padrik, J. Pindmaa, Financial Interests, Institutional, Full or part-time Employment: OÜ Antegenes. All other authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10